Piper Remains Constructive on Intra-Cellular Therapies (ITCI) Following Q3 Report; Affirms at 'Overweight'
Tweet Send to a Friend
Piper Jaffray affirms Intra-Cellular Therapies (Nasdaq: ITCI) with an Overweight rating and $22 price target following Q3 results and update ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
